Down 97% From Record Highs, Is Sundial Stock a Buy Right Now?

Despite the 97% decline in Sundial stock from its record high, it remains a risky bet for long-term investors due to poor fundamentals.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Canadian cannabis company Sundial Growers (NASDAQ:SNDL) has been among the worst performers on the bourses since the stock went public in August 2019. Soon after its initial public offer, SNDL stock was priced at a high of US$11.5 and is now trading 97% below that, at US$0.56.

Let’s see what impacted Sundial stock in the past and if it is a good contrarian buy right now.

Sundial has massively diluted shareholder wealth

A key reason for the underperformance of Sundial can be attributed to shareholder dilution. In the five-month period between September 2020 and February 2021, the company issued 1.15 billion shares to offset its cash burn and lower its debt balance.

Further, last September, Sundial disclosed it will reduce its product portfolio and liquidate low-margin items to improve the bottom line. Sundial’s revenue was impacted by COVID-19 as its sales in 2020 stood at $60.9 million, compared to $75.8 million in 2019. Due to its strategic decision to exit certain markets, Sundial’s revenue in the last 12 months stood at $47.26 million.

In Q3 of 2021, Sundial reported sales of $14.4 million, an increase of 57% on a sequential basis. The growth in revenue was due to higher retail sales and the acquisition of Inner Spirit Holdings. However, its cultivation and production revenue stood at $8.2 million in Q3 compared to $9.2 million in Q2 and $9.9 million in Q1.

Sundial has burnt $173 million from its operating activities in the last four quarters. In Q3, its cash burn was $56 million, compared to $20 million in the year-ago period. As the company continues to focus on its retail cannabis business as well as the acquisition of Alcanna, its cash burn number might increase in the near term.

Sundial ended Q3 of 2021 with $571 in cash, providing it with enough liquidity right now. However, the balance could erode swiftly if Sundial goes on an acquisition spree, resulting in further shareholder dilution.

What next for SNDL stock?

In Q4 of 2021, Wall Street expects Sundial to report sales of $13.25 million, an increase of 15.4% year over year. However, it’s also expected to end 2021 with a loss per share of $0.07 which translates to net losses of $168 million.

Now, Sundial’s revenue might increase to $625.4 million in 2022 due to the Alcanna acquisition, which is one of the largest liquor retailers in Canada. Further, Alcanna’s subsidiary, Nova Cannabis, owns and operates 78 retail outlets across several provinces.

SNDL stock is valued at a forward price to sales multiple of less than three, which is quite reasonable given its growth forecasts. Despite falling sales, Sundial’s focus on selling high-margin products allowed the company to report an adjusted EBITDA of $10.5 million in Q3 of 2021. Analysts expect SNDL to break even on an adjusted basis by the end of 2022.

The Foolish takeaway

Sundial remains a high-risk bet considering the possibility of further shareholder dilution and less than impressive revenue growth. I believe there are far better pot stocks you can buy right now, given the risk-reward profile of Sundial.

Should you invest $1,000 in Sndl right now?

Before you buy stock in Sndl, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Sndl wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »